WASHINGTON — The Meals and Drug Administration on Friday authorised teplizumab, a sort 1 diabetes drug developed by Sanofi, for youngsters aged 8 and older with stage 3 diabetes.
The drug was chosen to undergo a speedy overview program launched final yr by former FDA Commissioner Marty Makary, however the company missed its aim date of April 21 to ship a call.
STAT beforehand reported that Sanofi requested to tug its drug out of this system after former prime drug regulator Tracy Beth Høeg disagreed with a workers determination to approve the drug. It’s uncommon for a middle director, and significantly a political appointee like Høeg, to become involved in particular person scientific evaluations.
This text is unique to STAT+ subscribers
Unlock this text — plus day by day intelligence on Capitol Hill and the life sciences trade — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.